Consolidation of Tumorous Mandibular Ramus Defect During Denosumab Treatment for Rapidly Progressive Metastatic Breast Cancer
Standard
Consolidation of Tumorous Mandibular Ramus Defect During Denosumab Treatment for Rapidly Progressive Metastatic Breast Cancer. / Friedrich, Reinhard E; Madani, Elika.
in: ANTICANCER RES, Jahrgang 41, Nr. 10, 10.2021, S. 5081-5087.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Consolidation of Tumorous Mandibular Ramus Defect During Denosumab Treatment for Rapidly Progressive Metastatic Breast Cancer
AU - Friedrich, Reinhard E
AU - Madani, Elika
N1 - Copyright © 2021 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
PY - 2021/10
Y1 - 2021/10
N2 - BACKGROUND: Pharmacological inhibition of osteoclast activity is an essential component of oncological therapy for patients with bone metastases. In rare cases, medication-related osteonecrosis of the jaws (MRONJ) is observed. MRONJ can cause bone defects not inferior to primary or metastatic jaw neoplasms. Oral examination of patients on osteoclast-inhibiting medication aims to identify risk factors at an early stage and to initiate therapy. The current focus on osteoclast-inhibiting drugs in the maxillofacial region is MRONJ. Effects of the substances other than MRONJ are rarely reported.CASE REPORT: The female patient with metastatic breast cancer had developed extensive osteolysis of the mandibular ramus at the time of initial diagnosis. The patient was treated with denosumab. Seven months later, a significant reduction in the mandibular osteolytic zone was recorded. However, known bone metastases from other sites had increased in size during multimodal therapy, and further metastases were recorded.CONCLUSION: Jaw metastasis can shrink under denosumab therapy.
AB - BACKGROUND: Pharmacological inhibition of osteoclast activity is an essential component of oncological therapy for patients with bone metastases. In rare cases, medication-related osteonecrosis of the jaws (MRONJ) is observed. MRONJ can cause bone defects not inferior to primary or metastatic jaw neoplasms. Oral examination of patients on osteoclast-inhibiting medication aims to identify risk factors at an early stage and to initiate therapy. The current focus on osteoclast-inhibiting drugs in the maxillofacial region is MRONJ. Effects of the substances other than MRONJ are rarely reported.CASE REPORT: The female patient with metastatic breast cancer had developed extensive osteolysis of the mandibular ramus at the time of initial diagnosis. The patient was treated with denosumab. Seven months later, a significant reduction in the mandibular osteolytic zone was recorded. However, known bone metastases from other sites had increased in size during multimodal therapy, and further metastases were recorded.CONCLUSION: Jaw metastasis can shrink under denosumab therapy.
KW - Adult
KW - Bone Density Conservation Agents/adverse effects
KW - Bone Neoplasms/chemically induced
KW - Breast Neoplasms/drug therapy
KW - Denosumab/adverse effects
KW - Disease Progression
KW - Female
KW - Humans
KW - Mandibular Neoplasms/chemically induced
KW - Prognosis
U2 - 10.21873/anticanres.15324
DO - 10.21873/anticanres.15324
M3 - SCORING: Journal article
C2 - 34593458
VL - 41
SP - 5081
EP - 5087
JO - ANTICANCER RES
JF - ANTICANCER RES
SN - 0250-7005
IS - 10
ER -
